Sequential analysis of biological samples

• US 9,518,982 B2
• Filed: 11/03/2009
• Issued: 12/13/2016
• Est. Priority Date: 11/16/2006
• Status: Active Grant

• Current Assignee: Leica Microsystems Gmbh (Danaher Corporation)
• Original Assignee: General Electric Company
• Inventors: Sood, Anup, Montalto, Michael Christopher, Gerdes, Michael, Seel, Maximilian Lewis, Filkins, Robert John
• Primary Examiner(s): THOMAS, DAVID C
• Application Number:
  US12/611,299
• Publication Number:
  US 20100047925A1
• Time in Patent Office: 2,597 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12Q 1/68 involving nucleic acids
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/542 with steric inhibition or signal modification, e.g. fluorescent quenching
• CPC Class Codes: G01N 33/582 with fluorescent label
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Methods for detecting multiple targets in a biological sample are provided. The methods includes contacting the sample with a first probe; physically binding the first probe to a first target; observing a first signal from the first probe; applying a chemical agent to modify the first signal; contacting the sample with a second probe; physically binding the second probe to a second target; and observing a second signal from the second probe. The methods disclosed herein also provide for multiple iterations of binding, observing, signal modification for deriving information about multiple targets in a single sample. An associated kit and device are also provided.

Claims

1. A kit for detection of multiple targets in a biological sample, comprising:

multiple probes, wherein each probe comprises a binder and a fluorophore, wherein each probe is configured to specifically bind to a target via the binder, wherein the binder comprises a primary antibody and wherein the fluorophore is coupled to a secondary antibody that binds to the target via the primary antibody; and

at least one chemical agent in a concentration that, when applied to each probe, is configured to modify the fluorescence signal provided by the fluorophore of at least one probe without affecting the integrity of the binder in the at least one probe such that the primary antibody, when bound to the target, remains bound to the target after modification of the fluorescent signal by the at least one chemical agent under conditions in which the fluorophore is destroyed.

2. The kit of claim 1, wherein the at least one chemical agent is configured to modify the fluorescence signal provided by the fluorophores of all of the multiple probes.

3. The kit of claim 1, wherein the multiple probes comprise a first probe comprising a first binder and a first fluorophore, wherein the first probe is configured to specifically bind to a first target, and wherein the first signal generator is configured to provide a first fluorescence signal;

and a second probe comprising a second binder and a second fluorophore, wherein the second probe is configured to specifically bind to a second target, and wherein the second signal generator is configured to provide a second fluorescence signal.

4. The kit of claim 3, wherein the first target is a protein and the second target is a nucleic acid.

5. The kit of claim 1, wherein the target is a protein antigen.

6. The kit of claim 1, further comprising a morphological stain configured to provide a distinguishable signal that does not overlap with the fluorescence signal produced by the fluorophores of multiple probes.

7. The kit of claim 6, wherein the morphological stain is a compartmental marker.

8. The kit of claim 6, wherein the at least one chemical agent is incapable of modifying the signal provided by the morphological stain.

9. The kit of claim 1, wherein the at least one chemical agent is chosen from hydrogen peroxide, sodium hydroxide, or a periodate salt.

10. The kit of claim 1, wherein the multiple probes comprises at least one probe, the fluorophore of which is configured to provide a fluorescence signal that is not modified by the at least one chemical agent.

11. The kit of claim 1, wherein the binder is an antibody and the fluorophore is a cyanine dye.

17. The kit of claim 1, wherein the at least one chemical agent configured to modify the fluorescence signal is capable of the modifying at room temperature.

18. The kit of claim 1, wherein the at least one chemical agent configured to modify the fluorescence signal is a buffered sodium hydroxide solution having a pH of about 12.

19. The kit of claim 1, wherein the at least one chemical agent configured to modify the fluorescence signal is a hydrogen peroxide solution having a volume percentage of about 3%.

20. The kit of claim 1, wherein the at least one chemical agent configured to modify the fluorescence signal comprises a first solution comprising the at least one chemical agent configured to modify the fluorescence signal and a second solution comprising the at least one chemical agent configured to modify the fluorescence signal.

21. The kit of claim 1, wherein destruction of the fluorophore does not affect binding of the primary antibody with the secondary antibody such that the secondary antibody remains bound to the primary antibody after the destruction of the fluorophore.

22. The kit of claim 1, wherein the chemical agent does not destroy a fluorophore associated with a morphological stain.

23. The kit of claim 1, wherein the morphological stain is DAPI.

24. The kit of claim 1, wherein the chemical agent is configured to destroy the fluorophore but not the morphological stain after contact times of at least 30 minutes.

25. The kit of claim 1, wherein the chemical agent is configured to destroy the fluorophore such that an average pixel intensity of an imaged sample including the target after the destruction is less than 7×

a background average pixel intensity observed from the sample before application of the fluorophore.

12. A kit for detection of multiple targets in a biological sample, comprising:

a first probe, comprising a first binder and a first fluorophore, wherein the first probe is configured to specifically bind to a first target via the first binder, and wherein the first fluorophore is configured to provide a first fluorescence signal;

a second probe, comprising a second binder and a second fluorophore, wherein the second probe is configured to specifically bind to a second target via the second binder, and wherein the second fluorophore is configured to provide a second fluorescence signal;

a first chemical agent in a concentration that, when applied to each probe, is configured to modify the first fluorescence signal provided by the first fluorophore without affecting the integrity of the first binder such that the first binder, when bound to the first target, remains bound to the first target after modification of the first fluorescent signal by the first chemical agent under conditions in which the first fluorophore is destroyed; and

a second chemical agent configured to modify the second fluorescence signal provided by the second fluorophore without affecting the integrity of the second binder such that the second binder, when bound to the second target, remains bound to the second target after modification of the second fluorescent signal by the second chemical agent.

13. The kit of claim 12, wherein the first fluorophore is a Cy5 dye or a Cy7 dye, and the second fluorophore is a Cy3 dye.

14. The kit of claim 12, wherein the first target is a protein and the second target is a nucleic acid.

15. The kit of claim 12, wherein either the first chemical agent or the second chemical agent is an oxidizing agent.

16. A kit for detection of multiple proteins in a single tissue section, comprising:

a plurality of cyanine dye-labeled antibodies; and

at least one oxidizing agent in a concentration that, when applied to the cyanine dye-labeled antibodies, is configured to modify the cyanine fluorescence of at least one of the plurality of cyanine dye-labeled antibodies without affecting the integrity of the antibodies.